Healthcare company Novavax views its vaccine pact with Sanofi as a model for future collaborations. A dinner in Paris saw Sanofi reinitiate negotiations for a $9.5 billion deal to acquire Blueprint. In addition to the Blueprint acquisition, Sanofi is bolstering its partnerships, including those with Kymera and Gilead. It is investing in exploring Formation’s JAK/SYK inhibitor and fast-tracking a Superior IRAK4 Drug. It is also investing $20 billion in US research and manufacturing over the next decade. Overall, the landscape suggests Sanofi is increasing its strategic investments and partnerships to become a leading competitor within the biopharma marketplace.
Sanofi News Analytics from Mon, 23 Sep 2024 12:06:18 GMT to Fri, 27 Jun 2025 16:32:46 GMT - Rating +6 - Innovation +8 - Information +7 - Rumor +2
